All News

The FDA has expanded the approved use of Seattle Genetics’ Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.

The FDA has expanded the approved use of Seattle Genetics’ Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL).

A significant increase in e-cigarette use among middle school and high school students in the United States has driven an overall rise in youth tobacco consumption, according to survey results released by the FDA and the CDC.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The Committees voted 12 to 5 that the drug should be labeled as an abuse-deterrent product by the nasal route of abuse, but they voted 10 to 7 that the drug should not be labeled as an abuse-deterrent product by the intravenous route of abuse.

If what you are doing day-in and day-out is NOT creating new patients purchasing your products and services, why are you spending any time doing it?

The statement is intended to serve as a discussion guide for the risk factors, diagnosis, treatment and prevention of the disease.

The findings revealed that 78% of pharmacists across pharmacy settings look forward to playing a greater role in patient care and the majority expect to spend more time on patient-focused activities in the next 5 years.

NYU Langone Health discusses the challenges and benefits involved in starting or expanding a health system’s specialty pharmacy.

Study evaluates the association between body mass index in late adolescence and the incidence of pancreatic cancer in adulthood.

The FDA granted the designation to brentuximab vedotin (Adcetris) for this indication in combination with cyclophosphamide, doxorubicin, and prednisone.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Express Scripts announced the impending launch of a novel formulary designed to ease out-of-pocket cost burden for members by allowing health plans to cover lower list price drug products.

Research on nonalcoholic fatty liver disease (NAFLD) in persons infected with HIV revealed a prevalence of the condition of about 40%, suggesting the condition may be an underappreciated comorbidity in this population.

Direct-acting antivirals are a costly but highly-effective class of drugs for the treatment of hepatitis C that can cure most cases.

Emgality (Galcanezumab-gnlm) is a self-administered once monthly subcutaneous injection and the third in its class for the preventative treatment of migraine in adults.

Nonsteroidal anti-inflammatory drugs should be used as the first line treatment for acute gout.

Your current patients will make you richer faster, because they admire—even love you and adore you—for what you do for them already.

The health care setting has the largest and most diverse array of agents that are hazardous to humans.

Officials with the FDA noted that patients are sometimes being treated with medications that are not approved (including compounded medicines as well as hydromorphone, bupivacaine, fentanyl and clonidine) for use with an intrathecal implanted pump.

The AMA and CDC are working with their local offices, affiliates, and partners to promote and activate the campaign in their communities, with evidence-based materials to aid physicians and other health care providers in the screening, diagnosis and treatment process.

Millions worldwide dread the onset of debilitating migraines. There is a new drug class on the horizon that is thought to put a stop to the root of migraines.

The new formulary will allow health plans to cover lower list price products, such as new authorized alternatives to brand-name medications.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing.

One hundred percent of patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response at 12 weeks post treatment with 8 weeks of glecaprevir/pibrentasvir treatment.